Anticholinesterases & Reversal Agents

Reversal of neuromuscular blockade is one of the most testable corners of anaesthesia pharmacology. The story revolves around two strategies — the classic anticholinesterases (neostigmine, pyridostigmine, edrophonium) that flood the synapse with acetylcholine, and the modern selective relaxant binding agent sugammadex that physically chelates the relaxant. Understanding the mechanisms, the obligatory anticholinergic co-administration, and the limits of each agent is high yield for NEET PG.

Quick orientation — why we need reversal

Non-depolarising neuromuscular blocking drugs (aminosteroids: rocuronium, vecuronium, pancuronium; benzylisoquinoliniums: atracurium, cisatracurium) are competitive antagonists at the nicotinic (Nm) receptor of the motor end-plate. They occupy the two alpha subunits and prevent acetylcholine (ACh) from depolarising the muscle. At the end of surgery, residual block must be reversed to restore adequate respiration, airway protection, and a train-of-four ratio (TOFR) ≥ 0.9. Residual paralysis ("recurarisation") is a major cause of postoperative respiratory morbidity, hypoxaemia, and aspiration.

High-yield: Anticholinesterases reverse non-depolarising block only. They potentiate / prolong depolarising (succinylcholine, phase I) block because they increase ACh and also inhibit plasma pseudocholinesterase — never give neostigmine for phase I suxamethonium block.

Classification of reversal agents

Class	Drugs	Core mechanism	Reverses
Anticholinesterases (indirect)	Neostigmine, Pyridostigmine, Edrophonium	Inhibit acetylcholinesterase → ↑ synaptic ACh → outcompetes relaxant	Non-depolarising block
Selective relaxant binding agent	Sugammadex	Encapsulates aminosteroid relaxant (1:1) in plasma	Rocuronium > vecuronium (aminosteroids)
Investigational	Calabadion (cyclodextrin analogue)	Chelates both steroidal & benzylisoquinolinium	(Not in clinical use)

Anticholinesterases — subtypes by chemistry

• Reversible, carbamate (carbamylating): neostigmine, pyridostigmine, physostigmine — form a slowly hydrolysed carbamylated enzyme (duration minutes–hours).
• Reversible, non-covalent / electrostatic: edrophonium — short, rapid onset, used in the Tensilon test for myasthenia gravis.
• Irreversible, organophosphate: echothiophate, malathion, parathion, nerve agents (sarin) — phosphorylate the enzyme; "ageing" makes the bond permanent (relevant to OP poisoning, treated with atropine + pralidoxime/oximes).

Pharmacology of the anticholinesterases

Mechanism in depth

Acetylcholinesterase (AChE) normally hydrolyses ACh into choline + acetate within milliseconds. Neostigmine binds the esteratic site, donating a carbamyl group; the carbamylated enzyme is hydrolysed far more slowly than the acetylated enzyme, so functional enzyme is depleted and ACh accumulates. The rising ACh competes with the non-depolarising relaxant at the Nm receptor and shifts equilibrium toward neuromuscular transmission.

Reversal cascade:

AChE inhibition → ↑ synaptic ACh → ACh outcompetes relaxant at Nm receptor → end-plate depolarises → muscle contraction restored

High-yield: Because anticholinesterases work by raising ACh, they have a ceiling effect — once the enzyme is maximally inhibited, no further reversal is possible. Therefore neostigmine cannot reverse deep/profound block; there must be some spontaneous recovery first (ideally ≥ 2 twitches / T2 on TOF, or at least one visible twitch).

Pharmacokinetics & comparison

Feature	Neostigmine	Pyridostigmine	Edrophonium
Onset (reversal)	5–7 min (peak ~7–11)	Slowest (~12–16 min)	Fastest (1–2 min)
Duration	~60 min	Longest (~90 min)	Shortest (~10–60 min)
Usual reversal dose	0.04–0.07 mg/kg (max ~5 mg)	0.1–0.25 mg/kg	0.5–1 mg/kg
Crosses BBB	No (quaternary)	No (quaternary)	No (quaternary)
Paired anticholinergic	Glycopyrrolate	Glycopyrrolate	Atropine (onset match)

High-yield mnemonic — antimuscarinic pairing by onset: "Neostigmine ↔ Glyco; Edrophonium ↔ Atropine." Match the anticholinergic onset to the anticholinesterase onset. Slow neostigmine pairs with slower glycopyrrolate; fast edrophonium pairs with fast atropine.

Note that physostigmine is a tertiary amine — it crosses the blood–brain barrier and is used for central anticholinergic syndrome and as an antidote in atropine/scopolamine/TCA-induced delirium. The quaternary agents (neostigmine, pyridostigmine, edrophonium, glycopyrrolate) do not cross the BBB.

Muscarinic side effects & the need for an anticholinergic

Raising ACh is non-selective: it floods muscarinic receptors too, producing parasympathetic overactivity. Hence neostigmine is always co-administered with an antimuscarinic (glycopyrrolate or atropine) to block these effects while sparing the nicotinic reversal at the muscle.

Muscarinic effects (SLUDGE / DUMBELS pattern):

• Bradycardia, AV block, asystole (most dangerous)
• Bronchoconstriction and increased bronchial secretions
• Salivation, lacrimation
• Increased GI motility → nausea, vomiting, cramps; anastomotic stress (theoretical)
• Miosis
• Increased bladder tone

High-yield: Mnemonic for muscarinic excess — DUMBELS: Diarrhoea/Defecation, Urination, Miosis, Bradycardia/Bronchorrhoea/Bronchospasm, Emesis, Lacrimation, Salivation. Or SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis.

Glycopyrrolate vs Atropine

Feature	Glycopyrrolate	Atropine
Structure	Quaternary (no BBB)	Tertiary (crosses BBB)
Onset	Slower (~2–3 min)	Faster (~1 min)
Antisialagogue	More potent, longer	Less
CNS effects (central anticholinergic syndrome)	None	Yes (delirium, sedation)
Tachycardia	Less marked	More marked
Preferred with	Neostigmine (matched slow onset)	Edrophonium (matched fast onset)
Pregnancy / placenta	Does not cross	Crosses placenta

Sugammadex — the modern reversal agent

Sugammadex is a modified gamma-cyclodextrin: a ring of 8 sugar units forming a lipophilic central cavity with a hydrophilic exterior. It encapsulates the steroidal relaxant in a tight 1:1 host–guest complex in plasma, lowering free plasma relaxant concentration. This creates a diffusion gradient pulling rocuronium/vecuronium away from the neuromuscular junction back into plasma where it is captured. The complex is excreted unchanged in urine.

High-yield: Sugammadex selectively binds aminosteroid relaxants — rocuronium > vecuronium > pancuronium. It does NOT reverse benzylisoquinolinium agents (atracurium, cisatracurium, mivacurium) or succinylcholine.

Key advantages over neostigmine

• Reverses profound/deep block that neostigmine cannot (no twitches present).
• No ceiling effect and no muscarinic side effects → no anticholinergic needed.
• Extremely fast: with adequate dose, reversal of even intense rocuronium block in ~2–3 minutes — faster than spontaneous recovery from succinylcholine.
• Enables the "can't intubate, can't oxygenate" rescue: a large rocuronium intubating dose can be promptly reversed (16 mg/kg).

Sugammadex dosing (by depth of block)

Depth of block	TOF status	Sugammadex dose
Routine / moderate	T2 reappeared (TOFC 2)	2 mg/kg
Deep	1–2 post-tetanic counts, no TOF twitch	4 mg/kg
Immediate reversal of intubating dose	~3 min after rocuronium	16 mg/kg

Sugammadex — adverse effects & cautions

• Hypersensitivity / anaphylaxis (dose-related; can occur even in naïve patients).
• Bradycardia and rare cardiac arrest reported shortly after administration.
• Binds hormonal contraceptives (progestogen) → equivalent to a missed dose; advise barrier contraception for 7 days.
• Renal impairment: the complex is renally cleared — avoid in severe renal failure / CrCl < 30 mL/min (not removed well by standard dialysis, though high-flux helps).
• May prolong aPTT/PT transiently (clinical bleeding not clearly increased).
• Re-administering rocuronium soon after: use a non-steroidal relaxant (cisatracurium) or wait/use high re-dose.

High-yield: Sugammadex binds progesterone-containing oral contraceptives → treat as one missed pill; backup contraception 7 days. Frequently tested.

Clinical principles of reversal

Timing & monitoring approach (stepwise):

1. Confirm spontaneous recovery has begun — use a peripheral nerve stimulator; for neostigmine reversal aim for at least T2 (≥2 twitches on TOF). Never reverse profound block with neostigmine.
2. Choose agent — neostigmine for moderate block; sugammadex for deep block or rapid reversal of aminosteroid relaxant.
3. Co-administer anticholinergic with neostigmine (glycopyrrolate preferred).
4. Confirm adequacy — target TOFR ≥ 0.9 (quantitative monitoring) before extubation. Clinical signs (5-second head lift, sustained hand grip, adequate tidal volume) are unreliable for detecting residual block.
5. Watch for recurarisation, especially if antagonist is shorter-acting than the relaxant.

High-yield: Adequate reversal is defined by train-of-four ratio ≥ 0.9 (T4:T1). Clinical tests (head lift, grip) only exclude gross weakness, not subtle residual block.

Factors that potentiate / impair reversal

• Hypothermia, respiratory acidosis (hypercarbia), metabolic acidosis prolong block and impair neostigmine reversal.
• Hypokalaemia, hypocalcaemia, hypermagnesaemia (e.g., MgSO4 in pre-eclampsia) potentiate non-depolarising block.
• Aminoglycosides, polymyxins, tetracyclines, clindamycin potentiate block.
• Renal/hepatic impairment prolongs relaxants cleared by those routes.

Special / related uses of anticholinesterases

• Myasthenia gravis: pyridostigmine is the symptomatic drug of choice (longer duration, fewer GI effects than neostigmine). Edrophonium (Tensilon) test historically distinguished myasthenic crisis (improves) from cholinergic crisis (worsens).
• Atony of bladder & paralytic ileus / postoperative ileus: neostigmine. IV neostigmine is treatment of acute colonic pseudo-obstruction (Ogilvie syndrome).
• Glaucoma: echothiophate (rare now).
• Anticholinergic / atropine poisoning, TCA toxicity, central anticholinergic syndrome: physostigmine (crosses BBB).
• Reversal of central effects of scopolamine.
• Organophosphate poisoning: these are anticholinesterase poisons; treat with atropine + pralidoxime (oxime).

Complications & dangers

• Profound bradycardia/asystole if neostigmine given without/before adequate anticholinergic.
• Recurarisation / residual block → hypoxaemia, airway obstruction, aspiration.
• Paradoxical weakness ("neostigmine-induced block"): giving neostigmine when block has fully resolved (or in excess) can cause an open-channel / depolarising-type weakness because excess ACh overstimulates the end-plate. Hence do not over-dose; do not reverse a patient who is already fully recovered.
• Cholinergic crisis in myasthenics on excess pyridostigmine.
• Sugammadex: anaphylaxis, bradycardia, contraceptive failure.

Key differentials & distinctions

• Phase I vs Phase II suxamethonium block: Phase I (depolarising) is augmented by anticholinesterases; Phase II (desensitisation block after prolonged/large suxamethonium) resembles non-depolarising block and may respond to neostigmine — but reversal is cautious and best guided by monitoring.
• Depolarising vs non-depolarising fade: Non-depolarising block shows TOF fade and post-tetanic facilitation; phase I depolarising block shows no fade, no post-tetanic potentiation.
• Neostigmine vs Sugammadex selection — see comparison table below.

Feature	Neostigmine	Sugammadex
Mechanism	↑ ACh via AChE inhibition	Encapsulates relaxant
Reverses	All non-depolarisers	Aminosteroids only (roc > vec)
Reverses deep block	No (needs ≥ T2)	Yes (4 mg/kg) / immediate (16 mg/kg)
Anticholinergic needed	Yes (glyco/atropine)	No
Ceiling effect	Yes	No
Main risks	Bradycardia, bronchospasm, recurarisation	Anaphylaxis, ↓ contraceptive efficacy, renal caution
Speed	Minutes (slower)	Very fast (1–3 min)

Recently asked / exam angle

• Drug paired with neostigmine to prevent bradycardia → glycopyrrolate (commonest single-best-answer).
• Sugammadex reverses which relaxant → rocuronium (aminosteroid); does NOT reverse atracurium/cisatracurium/succinylcholine.
• Anticholinesterase that crosses BBB / used in central anticholinergic syndrome → physostigmine.
• Drug of choice for symptomatic myasthenia gravis → pyridostigmine.
• Edrophonium pairs with which anticholinergic → atropine (onset matching).
• TOF ratio target before extubation → ≥ 0.9.
• Sugammadex dose for immediate reversal of rocuronium intubating dose → 16 mg/kg.
• Why can't neostigmine reverse profound block → ceiling effect / requires spontaneous recovery (≥ T2).
• Anticholinesterase increasing duration of succinylcholine → mechanism: inhibits plasma pseudocholinesterase + raises ACh.
• Sugammadex + oral contraceptive interaction → equals one missed dose, advise barrier method 7 days.
• Drug for acute colonic pseudo-obstruction (Ogilvie) → neostigmine.

Rapid revision

• Anticholinesterases reverse non-depolarising block; they prolong phase I depolarising block — never use for suxamethonium.
• Neostigmine has a ceiling effect and needs ≥ 2 TOF twitches (some spontaneous recovery) before it works.
• Neostigmine + glycopyrrolate (matched slow onset); edrophonium + atropine (matched fast onset).
• Quaternary amines (neostigmine, pyridostigmine, edrophonium, glycopyrrolate) do not cross BBB; physostigmine (tertiary) does → used in central anticholinergic syndrome.
• Pyridostigmine = DOC for myasthenia gravis (long acting); edrophonium = Tensilon test.
• Muscarinic excess = DUMBELS / SLUDGE; most dangerous effect is bradycardia/asystole.
• Sugammadex = modified gamma-cyclodextrin; encapsulates aminosteroids (rocuronium > vecuronium); useless for benzylisoquinoliniums and succinylcholine.
• Sugammadex doses: 2 mg/kg (moderate, T2), 4 mg/kg (deep, PTC 1–2), 16 mg/kg (immediate rescue).
• Sugammadex: no anticholinergic needed, no ceiling, but causes anaphylaxis, bradycardia, reduces hormonal contraceptive efficacy, avoid in CrCl < 30.
• Adequate reversal = train-of-four ratio ≥ 0.9; clinical signs are unreliable.
• Hypothermia, acidosis, hypokalaemia, hypermagnesaemia and aminoglycosides all impair reversal / potentiate block.
• Over-dosing neostigmine on a fully recovered patient can cause paradoxical (open-channel) weakness.